002773.SZ SHZ
Chengdu Kanghong Pharmaceutical Group Co., Ltd
1W: +7.3%
1M: +7.5%
3M: -0.5%
YTD: -25.6%
1Y: -48.4%
3Y: +21.4%
5Y: +5.7%
¥21.80 ($3.25)
-0.55 (-2.46%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$1.4B
+15.9% ▲
5Y CAGR: +11.7%
Capital Expenditures
$159M
-14.8% ▼
5Y CAGR: -30.2%
Free Cash Flow
$1.3B
+16.0% ▲
Dividends Paid
$349M
-153.3% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$955M
-12.7% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$270M | $421M | $866M | $1.0B | $1.2B |
| Depreciation & Amort. | $118M | $149M | $158M | $226M | $230M |
| Stock-Based Comp. | $0 | $5M | $8M | $0 | $0 |
| Change in Working Capital | -$276M | -$270M | -$77M | -$67M | -$62M |
| Other Non-Cash Items | $701M | $306M | -$93M | $29M | $67M |
| Operating Cash Flow | $273M | $494M | $925M | $1.2B | $1.4B |
| — Investing Activities — | |||||
| Capital Expenditures | -$617M | -$569M | -$355M | -$139M | -$159M |
| Acquisitions (Net) | $37K | $81K | $21M | $10M | $0 |
| Investment Purchases | -$6.0B | -$4.3B | -$5.7B | -$4.6B | -$4.3B |
| Investment Sales | $6.0B | $4.1B | $5.8B | $4.7B | $4.4B |
| Other Investing | -$1M | -$9M | -$21M | $36M | -$377K |
| Investing Cash Flow | -$584M | -$803M | -$216M | $7M | -$112M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | -$2M | -$3M | $0 | -$1M |
| Stock Repurchased | -$346K | $0 | $0 | $0 | $0 |
| Dividends Paid | -$245M | -$92M | -$92M | -$138M | -$349M |
| Other Financing | $1.6B | $15M | $21M | $7M | $7M |
| Financing Cash Flow | $1.4B | -$79M | -$74M | -$130M | -$344M |
| Net Change in Cash | $1.0B | -$389M | $637M | $1.1B | $955M |
| Cash End of Period | $3.3B | $2.9B | $3.6B | $4.7B | $5.6B |
| Free Cash Flow | -$344M | -$75M | $570M | $1.1B | $1.3B |